The design and properties of 3-hydroxypyridin-4-one iron chelators with high pFe3+ values

Hider, Robert C.; Liu, Zu D.; Piyamongkol, Sirivipa

doi:10.1016/s0955-3886(00)00090-4

Cited by 26 publications

(25 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, to reduce drug toxicity and improve chelation efficiency, a range of hydroxypyridinone analogs that contain high pFe(III) values have been produced. This property allows such chelators to effectively scavenge iron at lower concentrations and also dissociate less easily (Hider et al, 2000;Liu and Hider, 2002b). Consequently, a lower amount of the partially coordinated complexes are formed, reducing the potential for ROS production.…”

Section: Evolution Of Iron Chelatorsmentioning

confidence: 99%

See 1 more Smart Citation

The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer

2005

View full text Add to dashboard Cite

Section: Evolution Of Iron Chelatorsmentioning

confidence: 99%

“…8), a 2-amido-3-hydroxypyrinidin-4(1H)-one containing a pFe(III) value of 21.7 compared with deferiprone at 19.4 (Hider et al, 2000;Liu et al, 2001). This novel ligand was observed to have enhanced iron chelation activity in a […”

Section: Evolution Of Iron Chelatorsmentioning

confidence: 99%

The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer

2005

View full text Add to dashboard Cite

“…The presence of urea, capable of broadening ferritin channels, strongly increases the effectiveness of chelation. There is still inadequate understanding of all the mechanisms of chelator entry to ferritin, mobilization of iron and exit of the formed complexes (13)(14)(15)(16).…”

Section: Resultsmentioning

confidence: 99%

N-Phthaloyl-glycine-hydroxamic acid as serum iron chelator in rats

Matijević-Sosa¹,

Samaržija²,

Honović³

et al. 2008

Acta Pharmaceutica

View full text Add to dashboard Cite

Major functions of iron, as an essential element for living organisms, are oxygen transport and its role in oxidative-reductive reactions that utilize its alternative ferrous--ferric states. Total body iron has to be strictly controlled because excess iron can be highly toxic, leading, through generation of reactive oxygen species (ROS), to iron overloading disorders (1, 2). Iron chelating therapy has long been the standard care for patients suffering from Thalassemias (anemias caused by mutation of globin genes) and other anemias, caused e.g. by renal dysfunction (lack of erythropoietin (EPO) production), and for patients receiving transfusion iron supplementation. Iron chelators are used to treat dialyzed patients; in kidney transplantation, cardiac diseases, malaria, iron poisoning, and can inhibit tumor cell growth. They are also used to stimulate EPO production (3-5).Various structures of iron chelates have been investigated but the best known and in use for more than 40 years is desferrioxamine (DFO), despite its poor membrane permeability, short shelf life, difficulties in application and expensiveness. DFO is a natural hydroxamic acid (HA) of the microorganism Streptomyces sp. and belongs to sideropho- The aim of this study was to investigate the activity of N-phthaloyl-glycine-hydroxamic acid (Phth-Gly-HA) as a new iron chelator in vivo to be used in iron overload diseases. After intraperitoneal application of Phth-Gly-HA to male rats (1 mg kg -1 body mass) once a day for seven days, iron serum level decreased by 21%, whereas the iron value dropped by 32% in female rats (1.5 mg kg -1 body mass).The results indicate that the tested substance has the ability to bind serum iron by complexation. Besides transferrin iron release, mobilization of ferritin iron is also possible.

show abstract

“…Apparently hexadentate ligands are the best iron chelators, and a recent study on a hydroxypyridinone derivative CP502 has shown good oral absorption and iron excretion, even though it is bidentate. [17] Glycosylcurcuminoids have the great advantage of being administrated by oral formulation in their acetylated form, and even though their high molecular weight hinders the diffusion processes through the GIT, high dosages are completely safe. Acetyl-glycosyl-curcuminoids can probably be absorbed by the GIT thanks to their high lipophilicity.…”

Section: Introductionmentioning

confidence: 99%

Glycosyl‐Curcuminoids as Potential New Chelating Agents in Iron Overload Chelation Therapy

et al. 2004

View full text Add to dashboard Cite

The iron(III) chelating ability of some glycosyl derivatives of curcuminoids is tested by means of UV, potentiometric and NMR studies. The pK a of the ligands and the stability constants of their Fe 3+ and Ga 3+ complexes are evaluated by UV spectroscopy. The only metal binding site of the ligand is the β-dioxo moiety; the glycosyl moiety does not interact with the metal ion at acidic pH values but it helps to stabilise metal/ligand (1:2) complexes by means of hydrophilic interactions. By comparing the pFe 3+ of our ligands with those

show abstract

The design and properties of 3-hydroxypyridin-4-one iron chelators with high pFe3+ values

Cited by 26 publications

References 22 publications

The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer

The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer

N-Phthaloyl-glycine-hydroxamic acid as serum iron chelator in rats

Glycosyl‐Curcuminoids as Potential New Chelating Agents in Iron Overload Chelation Therapy

Contact Info

Product

Resources

About